News Biomarker hailed as “game changer” in Parkinson’s Researchers have discovered a new biomarker for Parkinson’s that could be used to identify people at risk of the disease and profoundly change the way it is treated.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.